Pharmacokinetic effect of aprepitant on irinotecan in patients with colorectal cancer

被引：0
|
作者：
Nieva, J. J.
Webb, W.
Siuzdak, G.
机构：
[1] Scripps Canc Ctr, La Jolla, CA USA
[2] Scripps Res Inst, La Jolla, CA 92037 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19622
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer
    Nilofer Azad
    Arvind Dasari
    John Arcaroli
    Gretchen E. Taylor
    Daniel A. Laheru
    Michael A. Carducci
    Martine McManus
    Kevin Quackenbush
    John J. Wright
    Manuel Hidalgo
    Luis A. Diaz
    Ross C. Donehower
    Ming Zhao
    Michelle A. Rudek
    Wells A. Messersmith
    Investigational New Drugs, 2013, 31 : 345 - 354
  • [22] Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer
    Azad, Nilofer
    Dasari, Arvind
    Arcaroli, John
    Taylor, Gretchen E.
    Laheru, Daniel A.
    Carducci, Michael A.
    McManus, Martine
    Quackenbush, Kevin
    Wright, John J.
    Hidalgo, Manuel
    Diaz, Luis A., Jr.
    Donehower, Ross C.
    Zhao, Ming
    Rudek, Michelle A.
    Messersmith, Wells A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 345 - 354
  • [23] A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
    Fornaro, Lorenzo
    Masi, G.
    Bursi, S.
    Loupakis, F.
    Vasile, E.
    Antonuzzo, A.
    Chiara, S.
    Pfanner, E.
    Di Paolo, A.
    Bocci, G.
    Del Tacca, M.
    Falcone, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (05) : 965 - 969
  • [24] A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
    Lorenzo Fornaro
    G. Masi
    S. Bursi
    F. Loupakis
    E. Vasile
    A. Antonuzzo
    S. Chiara
    E. Pfanner
    A. Di Paolo
    G. Bocci
    M. Del Tacca
    A. Falcone
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 965 - 969
  • [25] Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer
    Melichar, B
    Touskova, M
    Vesely, P
    HEPATO-GASTROENTEROLOGY, 2002, 49 (46) : 967 - 970
  • [26] Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
    Nygren, P
    Hande, K
    Petty, KJ
    Fedgchin, M
    van Dyck, K
    Majumdar, A
    Panebianco, D
    de Smet, M
    Ahmed, T
    Murphy, MG
    Gottesdiener, KM
    Cocquyt, V
    van Belle, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (06) : 609 - 616
  • [27] Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
    Peter Nygren
    Kenneth Hande
    Kevin J. Petty
    Margaret Fedgchin
    Kristien van Dyck
    Anup Majumdar
    Debbie Panebianco
    Marina de Smet
    Tuli Ahmed
    M. Gail Murphy
    Keith M. Gottesdiener
    Veronique Cocquyt
    Simon van Belle
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 609 - 616
  • [28] A pharmacokinetic (PK) model for irinotecan and its metabolites in cancer patients.
    Klein, C
    Kastrissios, H
    Gupta, E
    Ratain, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 197 - 197
  • [29] Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction
    Raymond, E
    Boige, V
    Faivre, S
    Sanderink, GJ
    Rixe, O
    Vernillet, L
    Jacques, C
    Gatineau, M
    Ducreux, M
    Armand, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4303 - 4312
  • [30] Irinotecan in the treatment of colorectal cancer
    Fuchs, Charles
    Mitchell, Edith P.
    Hoff, Paulo M.
    CANCER TREATMENT REVIEWS, 2006, 32 (07) : 491 - 503
12345